Revista Espanola De Medicina Nuclear E Imagen Molecular最新文献

{"title":"Relación entre el estado de HER2 adquirido a partir de los datos patológicos y los parámetros metabólicos obtenidos mediante [18F]FDG PET/TC pretratamiento en adenocarcinomas gástricos","authors":"M.N. Acar Tayyar ,&nbsp;M.Ö. Tamam ,&nbsp;G.B. Babacan ,&nbsp;M.C. Şahin ,&nbsp;H. Özçevik ,&nbsp;S. Şengiz Erhan ,&nbsp;A.E. Öztürk","doi":"10.1016/j.remn.2024.500080","DOIUrl":"10.1016/j.remn.2024.500080","url":null,"abstract":"<div><h3>Objective</h3><div>Overexpression of Human Epidermal Growth Factor Receptor 2 (HER2) is thought to be more aggressive in gastric cancer. This study aimed to evaluate the predictability of HER2 status and other prognostic pathologic parameters using [¹⁸F]FDG PET/CT and to investigate its impact on survival.</div></div><div><h3>Methods</h3><div>Pretreatment metabolic parameters measured by [¹⁸F]FDG PET/CT as a prognostic factor were retrospectively evaluated in 117 HER2-analysed patients. The relationship between pathological data, tumor metabolic characteristics, and distant metastases was examined, and the effect on survival was investigated.</div></div><div><h3>Results</h3><div>Among the 117 patients, 17.1% were HER2-positive (HER2⁺), and 82.9% were HER2-negative (HER2⁻). There was no significant association between PET/CT parameters in the HER2⁺ and HER2⁻ patient groups. HER2⁺ patients had higher 1- and 3-year survival expectations than HER2⁻ patients (80-37.9%; 47.5-20%; respectively). There was no statistically significant difference in overall survival. In Cox-regression analysis, while the presence of vascular invasion, local invasion, and distant metastasis were poor prognostic factors, HER2 was not a prognostic factor. Vascular invasion and local invasion (T3/T4) were also associated with higher SUVmax values. Patients with distant metastases had significantly higher SUVmax, SUVmean, and TLG.</div></div><div><h3>Conclusion</h3><div>This study showed no association between HER2 expression and [¹⁸F]FDG PET/CT metabolic parameters. However, regardless of HER2 status, the results indicated distant metastasis, local invasion, and vascular invasion could be associated with primary tumor metabolism. PET/CT parameters predict tumor aggressiveness and disease prognosis better than HER2 status.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 4","pages":"Article 500080"},"PeriodicalIF":1.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144557696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Estado del arte y perspectivas futuras de nuevos radionúclidos en Medicina Nuclear: Parte III","authors":"I. Torres ,&nbsp;R. Ramos ,&nbsp;M.L. Domínguez ,&nbsp;J.J. Rosales ,&nbsp;A. Roteta ,&nbsp;E. Prieto ,&nbsp;L. Sancho ,&nbsp;M. de Arcocha ,&nbsp;G. Quincoces ,&nbsp;en nombre del Grupo de Oncología de la SEMNIM","doi":"10.1016/j.remn.2025.500161","DOIUrl":"10.1016/j.remn.2025.500161","url":null,"abstract":"<div><div>In this third installment of the continuing education series, the clinical and therapeutic applications of zirconium, astatine and thorium are analyzed in depth. Although they are not described as theragnostic pairs, each of these radionuclides plays a fundamental role in precision medicine, which is rapidly advancing within Nuclear Medicine.</div><div>We begin by analyzing zirconium-89, a positron emitter whose long half-life makes it particularly suitable for labeling large molecules with slow kinetics, such as antibodies, playing a crucial role in immunotherapy. The use of astatine-211, an alpha-emitting radionuclide with a simple decay scheme and chemical behavior similar to iodine, is also discussed. Its main challenge lies in its production, as it requires cyclotrons capable of generating highly energetic alpha particle beams. Furthermore, thorium-227, a 100% alpha emitter, is reviewed. This radionuclide exhibits excellent chelation properties, enabling its conjugation with tumor-targeting molecules to produce thorium-labeled conjugates. While this technique is yielding promising preclinical results, the use of thorium faces challenges, including the potential separation of radium-223 from the molecule and the dependence of activity measurements on the time of production. Since it takes 100 days to reach equilibrium, activity assessment is based on photons emitted by its daughter radionuclides.</div><div>Despite these challenges, these radionuclides are driving the evolution of precision medicine, expanding therapeutic and diagnostic possibilities within Nuclear Medicine.</div><div>Nuclear Medicine.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 4","pages":"Article 500161"},"PeriodicalIF":1.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144557695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Redefiniendo la localización preoperatoria basada en imágenes de los adenomas en pacientes con hiperparatiroidismo primario candidatos a cirugía mínimamente invasiva","authors":"S. Casanueva-Eliceiry ,&nbsp;M. Manyalich-Blasi ,&nbsp;A. Farré-Melero ,&nbsp;A. Niñerola-Baizán ,&nbsp;D. Saavedra ,&nbsp;M. Mora-Porta ,&nbsp;F.A. Hanzu ,&nbsp;A. Orois ,&nbsp;M. Squarcia ,&nbsp;M. Rodrigo-Calvo ,&nbsp;M. Tormo-Ratera ,&nbsp;K. Quintero-Martinez ,&nbsp;D. Fuster-Pelfort ,&nbsp;O. Vidal-Pérez ,&nbsp;S. Vidal-Sicart","doi":"10.1016/j.remn.2024.500091","DOIUrl":"10.1016/j.remn.2024.500091","url":null,"abstract":"<div><h3>Background and objectives</h3><div>To compare the diagnostic accuracy of [¹⁸F]-Fluorocholine (FCH) PET/CT with conventional [^99mTc]Tc-MIBI scintigraphy and cervical ultrasound (USG) for the preoperative localization of hyperfunctioning parathyroid tissue (HFPT) in patients with primary hyperparathyroidism (PHPT).</div></div><div><h3>Materials and methods</h3><div>This prospective study included 90 patients diagnosed with PHPT who underwent [¹⁸F]F-CH PET/CT, [^99mTc]Tc-MIBI SPECT/CT and Neck USG. The diagnostic accuracy of each imaging modality was assessed using intraoperative findings and histopathological confirmation as the gold standard. The localization accuracy was evaluated based on specific quadrant detection, laterality, and ectopic gland identification. The study also explored the correlation between imaging findings and biochemical parameters, including preoperative and postoperative PTH and calcium levels.</div></div><div><h3>Results</h3><div>[¹⁸F]F-CH PET/CT demonstrated superior accuracy in detecting pathological parathyroid glandscompared to [^99mTc]Tc-MIBI SPECT/CT and USG. [¹⁸F]F-CH PET/CT correctly identified 98.9% of patientswith pathological glands, with a specific location accuracy of 93.2%, 65.9% and 38.8% for [¹⁸F]F-CH PET/CT,[^99mTc]Tc-MIBI SPECT/CT and USG, respectively.</div><div>For ectopic adenomas, FCH PET/CT achieved an accuracy of 100% (4/4), while MIBI and neck ultrasound identified these in 50% (2/4) and 0% (0/4) of cases, respectively.</div><div>There were two cases of multiglandular disease, [¹⁸F]F-CH PET/CT and [99mTc]Tc-MIBI each detected one gland in one case (50%) while USG detected none; in the other case, [¹⁸F]F-CH PET/CT and USG identified both glands (100%), and [99mTc]Tc-MIBI detected none.</div><div>Significant correlations were observed between SUVmax values from [¹⁸F]F-CH PET/CT and gland size, weight, and preoperative PTH levels.</div></div><div><h3>Conclusions</h3><div>[¹⁸F]F-CH PET/CT outperformed conventional imaging modalities in the preoperative localization of HFPT, particularly in challenging cases such ectopic or multiglandular disease. These findings support its potential as an effective and reliable imaging tool for the management of primary hyperparathyroidism.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 4","pages":"Article 500091"},"PeriodicalIF":1.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144557698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: «Evaluación del papel de la sarcopenia y los parámetros [18F]FDG PET/TC en el pronóstico del adenocarcinoma ductal pancreático»","authors":"D. Mut Surmeli","doi":"10.1016/j.remn.2025.500125","DOIUrl":"10.1016/j.remn.2025.500125","url":null,"abstract":"","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 3","pages":"Article 500125"},"PeriodicalIF":1.6,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143868933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Estado del arte y perspectivas futuras de nuevos radionúclidos en Medicina Nuclear: Parte II","authors":"L. Sancho ,&nbsp;A. Roteta ,&nbsp;I. Torres ,&nbsp;M. de Arcocha ,&nbsp;R. Ramos ,&nbsp;M.L. Domínguez ,&nbsp;J.J. Rosales ,&nbsp;E. Prieto ,&nbsp;G. Quincoces ,&nbsp;en nombre del Grupo de Oncología de la SEMNim","doi":"10.1016/j.remn.2025.500128","DOIUrl":"10.1016/j.remn.2025.500128","url":null,"abstract":"<div><div>The state of the art and future perspectives of new radionuclides in Nuclear Medicine continue to evolve, driven by the development of isotopes with innovative applications in theragnostics.</div><div>In this second part of the continuing education series, the clinical and therapeutic applications of terbium, actinium, and bismuth are analyzed in depth. The use of the 4<!--> <!-->terbium isotopes (terbium-149, terbium-152, terbium-155, and terbium-161) is described, offering a versatile system for both diagnosis and treatment due to their chemical similarity to lutetium-177, along with the challenges related to their production and availability. Additionally, actinium-225, a powerful alpha-emitting radionuclide, is reviewed for its growing role in targeted alpha therapy, particularly in prostate cancer and neuroendocrine tumors. Finally, bismuth-213, derived from actinium-225, is analyzed for its short half-life, making it a viable option for localized and selective therapies.</div><div>Despite technical and production challenges, these radionuclides are driving the evolution of precision medicine, expanding therapeutic and diagnostic possibilities in Nuclear Medicine.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 3","pages":"Article 500128"},"PeriodicalIF":1.6,"publicationDate":"2025-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143869302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Utilidad del [18F]FDG PET/TC en el manejo del linfoma óseo primario","authors":"M. Mangas Losada ,&nbsp;I. Garcia Megías ,&nbsp;R. Mangas Losada ,&nbsp;L.G. Romero Robles ,&nbsp;X. Boulvard Chollet ,&nbsp;R. Ramírez Lasanta","doi":"10.1016/j.remn.2025.500126","DOIUrl":"10.1016/j.remn.2025.500126","url":null,"abstract":"","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 3","pages":"Article 500126"},"PeriodicalIF":1.6,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143867270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Análisis de variables dosimétricas y clínicas en el tratamiento de los tumores neuroendocrinos con [177Lu]Lu-DOTA-TATE","authors":"P. Mínguez Gabiña ,&nbsp;T. Monserrat Fuertes ,&nbsp;B. Santos Zorrozua ,&nbsp;A. Esteban Figueruelo ,&nbsp;M.A. Astudillo Sarmiento ,&nbsp;A. Peña Fuentes ,&nbsp;I. Vinagre Pérez ,&nbsp;E. Rodeño Ortiz de Zarate ,&nbsp;I.L. Fernández Tercero","doi":"10.1016/j.remn.2024.500089","DOIUrl":"10.1016/j.remn.2024.500089","url":null,"abstract":"<div><h3>Purpose</h3><div>The main objectives were to study differences between the first and the fourth cycle in dosimetry variables in patients treated for neuroendocrine tumours with four cycles of [¹⁷⁷Lu]Lu-DOTA-TATE, as well as to look for absorbed dose–effect correlations aiming to help individualise and optimise this therapy for future patients.</div></div><div><h3>Material and methods</h3><div>SPECT based dosimetry of tumour lesions and kidneys was performed in the first and the fourth cycles of the [¹⁷⁷Lu]Lu-DOTA-TATE treatments for 17 patients from 2020 to 2023. Clinical variables of interest were collected in order to look for correlations with some dosimetry variables. Statistical analysis was performed using the R software.</div></div><div><h3>Results</h3><div>Regarding dosimetry variables, for lesions a significant decrease in absorbed dose, mass and initial activity between the first and fourth cycles was observed. For kidneys, a significant increase in absorbed dose was observed. Effective decay constants did not significantly change neither for lesions nor for kidneys. The relative decrease in lesion masses correlated with their total absorbed dose. Total absorbed doses to kidneys were well below the toxicity limits mostly used in this therapy. Relative decr</div><div>ease in lesion absorbed doses was significantly lower for tumour primary sites in ileum and jejunum compared to those in pancreas. Moreover, radiological response correlated with clinical response.</div></div><div><h3>Conclusions</h3><div>The results seem to indicate that the current treatment scheme could be optimised in order to obtain better treatment outcomes.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 3","pages":"Article 500089"},"PeriodicalIF":1.6,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143868613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlación entre los hallazgos de la PET/TC con [18F]FDG y los subtipos histológicos de adenocarcinoma de pulmón que se presentan como opacidad en vidrio deslustrado","authors":"H. Ji ,&nbsp;S. Jiang ,&nbsp;C. Sun ,&nbsp;T. Liu ,&nbsp;G. Yang ,&nbsp;L. Zhang ,&nbsp;J. Sun ,&nbsp;J. Wu","doi":"10.1016/j.remn.2024.500087","DOIUrl":"10.1016/j.remn.2024.500087","url":null,"abstract":"<div><h3>Objective</h3><div>The aim of this study is to analyze the correlation between [18F]-FDG PET/CT (positron emission tomography/computed tomography) findings and pathological subtypes of lung adenocarcinoma with ground-glass opacity (GGO).</div></div><div><h3>Materials and methods</h3><div>88 patients were included in this study, which underwent [18F]-FDG PET/CT and were finally diagnosed with lung adenocarcinoma. A total of 90 GGO lesions were analyzed. The size and SUV_max of all lesions were measured, the proportion of solid components of GGO in lesions was calculated, and quantitative classification was performed. The above GGO lesions were divided into three groups based on the 2011 IASLC/ATS/ERS lung adenocarcinoma pathological classification, namely good prognosis group, relatively good prognosis group and poor prognosis group. Chi-square test, independent sample t test, and analysis of variance were used for statistical analysis.</div></div><div><h3>Results</h3><div>There was a negative correlation between the SUV_max and quantitative classification value (<em>r</em> =−0.638, <em>P</em> &lt; 0.001). Atypical adenomatous hyperplasia (AAH), acinar predominant adenocarcinoma (APA), lepidic predominant adenocarcinoma (LPA), papillary predominant adenocarcinoma (PPA), and solid pre-dominant adenocarcinoma (SPA) had significant differences in GGO lesion size, SUV_max, and quantitative classification value (<em>F</em> = 3.849, <em>P</em> = 0.019; <em>F</em> = 27.420, <em>P</em> &lt; 0.001; <em>F</em> = 4.353, <em>P</em> = 0.002). There were significant differences in GGO lesion size, SUV_max, and quantitative classification value among the good prognosis group, relatively good prognosis group, and poor prognosis group (<em>F</em> = 5.626, <em>P</em> = 0.011; <em>F</em> = 37.587, <em>P</em> &lt; 0.001; <em>F</em> = 5.119, <em>P</em> = 0.008).</div></div><div><h3>Conclusion</h3><div>GGO lesion size, SUV_max, and quantitative classification value are correlated with different pathological subtypes and can be used to evaluate the prognosis of lung adenocarcinoma with GGO.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 3","pages":"Article 500087"},"PeriodicalIF":1.6,"publicationDate":"2025-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143868614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Malacoplaquia renal y pulmonar con afectación mediastínica que simula en estudio PET/TC con [18F]FDG una neoplasia sincrónica","authors":"J.R. Garcia,&nbsp;A. Compte,&nbsp;S. Romero,&nbsp;L. Mont,&nbsp;L. Pinilla,&nbsp;E. Riera","doi":"10.1016/j.remn.2025.500124","DOIUrl":"10.1016/j.remn.2025.500124","url":null,"abstract":"","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 3","pages":"Article 500124"},"PeriodicalIF":1.6,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143868721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Resultados e incidencia de hipotiroidismo tras el tratamiento del hipertiroidismo con yodo radiactivo a dosis bajas","authors":"K.-H. Lin ,&nbsp;J.-C. Wu ,&nbsp;M.-C. Wu","doi":"10.1016/j.remn.2024.500056","DOIUrl":"10.1016/j.remn.2024.500056","url":null,"abstract":"<div><h3>Objective</h3><div>The study aimed to analyze the outcome of low-dose radioactive iodine (RAI) treatment for hyperthyroidism, disclose whether age and gender influence the outcome, and determine the incidence and onset time of hypothyroidism following low-dose RAI.</div></div><div><h3>Material and methods</h3><div>A total of 158 patients who received doses less than 370<!--> <!-->Mbq RAI were enrolled in the study. Treatment outcome and incidence of hypothyroidism were compared between different gender (45 male vs. 113 female), age (77 patients ≥<!--> <!-->45<!--> <!-->years old vs. 81 patients &lt;<!--> <!-->45<!--> <!-->years old) and dose (39 patients receiving higher doses RAI vs. 119 receiving lower dose with a cutoff of 222<!--> <!-->MBq) groups. Treatment outcomes were categorized into post-treatment hypothyroidism, treatment failure (persistent hyperthyroidism), and euthyroidism. In those becoming hypothyroid, time to develop hypothyroidism was calculated for cumulative incidences over time.</div></div><div><h3>Results</h3><div>Out of 158 patients, 47 (29.7%) developed hypothyroidism, 101 (63.9%) had treatment failure, and 10 (6.3%) remained euthyroid after treatment. Response rates (33.6% vs. 43.5%, <em>P</em> <!-->=<!--> <!-->.260) and hypothyroidism incidences (26.9% vs. 38.5%, <em>P</em> <!-->=<!--> <!-->.170) did not differ significantly between lower and higher dose groups, neither between lower and higher age groups (<em>P</em> <!-->=<!--> <!-->.69 in response rates and <em>P</em> <!-->=<!--> <!-->.75 in hypothyroidism incidence). Females exhibited higher response rates (42.5% vs. 20.0%, <em>P</em> <!-->=<!--> <!-->.008) and hypothyroidism incidence (46.3% vs. 13.3%, <em>P</em> <!-->=<!--> <!-->.004) compared to males. Hypothyroidism onset occurred at a mean of 24.0<!--> <!-->±<!--> <!-->29.2 months, and the cumulative incidences over time were 47% and 60% in six and twelve months, respectively.</div></div><div><h3>Conclusions</h3><div>Low-dose RAI has a low response rate for treating hyperthyroidism. Although there may be a lower incidence of hypothyroidism following low-dose RAI compared to high-dose RAI, hypothyroidism may occur early after treatment. Besides, females have higher response rates but more incidence of hypothyroidism. The balance between the risks and benefits of using low-dose RAI should be taken into deliberate consideration.</div></div>","PeriodicalId":48986,"journal":{"name":"Revista Espanola De Medicina Nuclear E Imagen Molecular","volume":"44 2","pages":"Article 500056"},"PeriodicalIF":1.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143510912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}